Atypical femoral fracture (AFF) is a well-recognised adverse effect of long-term bisphosphonate use necessitating the incorporation of drug holidays during treatment of osteoporosis. Less commonly reported is AFF secondary to denosumab. Use of denosumab for the treatment of osteoporosis and prevention of skeletal related events in the primary care and oncological settings respectively is increasing. We present a series of three cases where AFF occurred in individuals treated with denosumab. This is followed by a discussion of potential risk factors and complexities surrounding the management of AFF, particularly with regards to cessation of denosumab. Our case series contributes to increasing clinician and consumer awareness of AFF secondary to denosumab use.